Chemicals Press Releases
SEE OTHER BRANDS

Following the chemical industry news from the world

Chemicals Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Chemicals Press Releases.

Press releases published on May 7, 2025

Veeco Reports First Quarter 2025 Financial Results

Veeco Reports First Quarter 2025 Financial Results

First Quarter 2025 Highlights: Revenue of $167.3 million, compared with $174.5 million in the same period last year GAAP net income of $11.9 million, or $0.20 per diluted share, compared with $21.9 million, or $0.37 per diluted share in the same period …

Q3 2025 Results: Lesaka delivers on guidance, reaffirms FY2025 outlook and projects positive net income in FY2026

Q3 2025 Results: Lesaka delivers on guidance, reaffirms FY2025 outlook and projects positive net income in FY2026

JOHANNESBURG, May 07, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the third quarter of fiscal 2025 (“Q3 2025”). Q3 2025 performance: Revenue of $135.7 million (ZAR 2.5 billion) was at the midpoint …

Texas Capital Announces Expansion of Corporate and Investment Banking Division

Texas Capital Announces Expansion of Corporate and Investment Banking Division

DALLAS, May 07, 2025 (GLOBE NEWSWIRE) -- Texas Capital Securities, a subsidiary of Texas Capital Bancshares, Inc. (NASDAQ: TCBI), today announced a significant expansion of the services offered by its Corporate and Investment Bank. The additions to …

Teekay Corporation Ltd. First Quarter 2025 Business Update; and Declares a Special Dividend

Teekay Corporation Ltd. First Quarter 2025 Business Update; and Declares a Special Dividend

HAMILTON, Bermuda, May 07, 2025 (GLOBE NEWSWIRE) -- Teekay Corporation Ltd. (Teekay or the Company) (NYSE:TK) today reported a business update for the three months ended March 31, 2025. The business update and Teekay Group’s earnings presentation are …

Health Catalyst Reports First Quarter 2025 Results

Health Catalyst Reports First Quarter 2025 Results

SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended …

Clarisil Pro Under Review: Proven Hearing Loss Support Supplement with Secret Navajo Remedy

Clarisil Pro Under Review: Proven Hearing Loss Support Supplement with Secret Navajo Remedy

New York, May 07, 2025 (GLOBE NEWSWIRE) -- In This Article, You’ll Discover: Why hearing loss is on the rise—and how environmental and lifestyle factors play a major role The most common causes of auditory decline, including inflammation, nutritional …

Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first …

Sunrun Reports First Quarter 2025 Financial Results

Sunrun Reports First Quarter 2025 Financial Results

Aggregate Subscriber Value of $1.2 billion in Q1, 23% growth year-over-year Contracted Net Value Creation of $164 million, or $0.72 per share, 104% growth year-over-year Cash Generation of $56 million in Q1, the fourth consecutive quarter of positive Cash …

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year New non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio …

Fluence Energy, Inc. Reports Second Quarter 2025 Results; Lowers Full Year 2025 Guidance, Citing Decisions to Pause Certain U.S. Projects Due to Tariff Uncertainty

Fluence Energy, Inc. Reports Second Quarter 2025 Results; Lowers Full Year 2025 Guidance, Citing Decisions to Pause Certain U.S. Projects Due to Tariff Uncertainty

ARLINGTON, Va., May 07, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its …

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration …

New Toll Brothers Copperhaven Model Home Opens in West Jordan, Utah

New Toll Brothers Copperhaven Model Home Opens in West Jordan, Utah

WEST JORDAN, Utah, May 07, 2025 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL) the nation’s leading builder of luxury homes, today announced the grand opening of the new model home at its Copperhaven by Toll Brothers community located in the heart of …

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment …

FormFactor Announces Participation at Upcoming Conferences

FormFactor Announces Participation at Upcoming Conferences

LIVERMORE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq: FORM) is pleased to announce its participation in the following investor conferences: B. Riley 25th Annual Investor Conference Location: The Ritz-Carlton, Marina del Rey Date:  …

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose- …

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System

WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and …

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund …

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML …

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service